Erica J. Young , Laszlo Radnai , Victor Prikhodko , Courtney A. Miller
{"title":"Novel therapeutics in development for the treatment of stimulant-use disorder","authors":"Erica J. Young , Laszlo Radnai , Victor Prikhodko , Courtney A. Miller","doi":"10.1016/j.conb.2024.102898","DOIUrl":null,"url":null,"abstract":"<div><p>Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant-use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.</p></div>","PeriodicalId":10999,"journal":{"name":"Current Opinion in Neurobiology","volume":"87 ","pages":"Article 102898"},"PeriodicalIF":4.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0959438824000606/pdfft?md5=9645fde3049a3b948c0398d0ad218e3d&pid=1-s2.0-S0959438824000606-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959438824000606","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant-use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.
期刊介绍：
Current Opinion in Neurobiology publishes short annotated reviews by leading experts on recent developments in the field of neurobiology. These experts write short reviews describing recent discoveries in this field (in the past 2-5 years), as well as highlighting select individual papers of particular significance.
The journal is thus an important resource allowing researchers and educators to quickly gain an overview and rich understanding of complex and current issues in the field of Neurobiology. The journal takes a unique and valuable approach in focusing each special issue around a topic of scientific and/or societal interest, and then bringing together leading international experts studying that topic, embracing diverse methodologies and perspectives.
Journal Content: The journal consists of 6 issues per year, covering 8 recurring topics every other year in the following categories:
-Neurobiology of Disease-
Neurobiology of Behavior-
Cellular Neuroscience-
Systems Neuroscience-
Developmental Neuroscience-
Neurobiology of Learning and Plasticity-
Molecular Neuroscience-
Computational Neuroscience
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
